With India expected to spend Rs 75,000 crore (Centre, states and private sector) in calendar year 2021 on vaccines, including Rs 3,200 crore spent till April-end to combat Covid, Serum Institute of India (SII) and Bharat Biotech would be the key beneficiaries. According to an analyst report by Investec, Serum Institute and Bharat Biotech will control over 67 per cent (Serum Institute 43 per cent and Bharat Biotech 24 per cent) of the value market share and 73 per cent in terms of volumes.
Sputnik V, the Russian Covid vaccine, will be the third player with a 14 per cent share. Based on ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU